# A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

Source: https://onco.cc/trials/nct05662397/  
OnCo record `nct05662397` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Cemiplimab in advanced solid tumours, run by HotSpot Therapeutics, Inc, active and no longer recruiting.

## Summary

A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody is a phase 1/2 interventional study registered as NCT05662397 by HotSpot Therapeutics, Inc, with 77 participants enrolled, started 2023-03-15 and due to reach its primary completion in 2025-12-31. Interventions recorded: HST-1011 and Cemiplimab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05662397
- Phase: 1/2
- Setting: An Open Label, Phase 1/2 Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors
- Sponsor: HotSpot Therapeutics, Inc
- Enrolled: 77

## Sources

- ClinicalTrials.gov NCT05662397: https://clinicaltrials.gov/study/NCT05662397

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Cemiplimab](https://onco.cc/drugs/cemiplimab/), [HST-1011](https://onco.cc/drugs/hst-1011/)

---
JSON: https://onco.cc/api/v1/entities/nct05662397.json